ADVANCED KRAS G12D MUTANT SOLID TUMORS
Clinical trials for ADVANCED KRAS G12D MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED KRAS G12D MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets tough cancers with KRAS G12D mutation
Disease control OngoingThis study tests a new drug called HRS-4642 combined with other cancer medicines in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to check safety, find the best dose, and see if the combination shrinks tumors. About 47 adults aged …
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 11:03 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human testing
Disease control OngoingThis early-stage study tests a new drug called HRS-4642 in about 100 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goal is to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug shrinks tum…
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC